Arrowhead Plozasiran Data Supports Triglyceride Reduction And Valuation Upside Potential
Arrowhead Pharmaceuticals released two year extension data for its RNAi therapy plozasiran in patients with severe and moderate hypertriglyceridemia. The study showed sustained triglyceride reduction alongside a favorable safety profile over the long term. Results were presented at a major cardiology conference and focus on patient groups at high risk of acute pancreatitis with limited treatment options. For investors tracking NasdaqGS:ARWR, the plozasiran update arrives after a mixed share...